Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles

被引:58
|
作者
Crich, Simonetta Geninatti
Lanzardo, Stefania
Alberti, Diego
Belfiore, Simona
Ciampa, Anna
Giovenzanaz, Giovanni B.
Lovazzano, Clara
Pagliarin, Roberto
Aime, Silvio
机构
[1] Univ Turin, Ctr Mol Imaging, I-10126 Turin, Italy
[2] Univ Turin, Dept Chem IFM, Turin, Italy
[3] Univ Turin, Dept Clin & Biol Sci, Orbassano, Italy
[4] Uni Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut & Farm, Novara, Italy
[5] Univ Milan, Dipartimento Chim Organ Ind, Milan, Italy
来源
NEOPLASIA | 2007年 / 9卷 / 12期
关键词
magnetic resonance imaging; LDL; Gd complexes; tumor; dual imaging probe;
D O I
10.1593/neo.07682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gd-DO3A-diph and Gd-AAZTAC17 are lipophilic magnetic resonance imaging (MRI) agents that display high affinity for low-density lipoprotein (LDL) particles. However, on binding to LDL, Gd-DO3A-diph shows a decreased hydration that results in a lower enhancement of water proton relaxation rate. Conversely, Gd-AAZTAC17 displays a strong relaxation enhancement at the imaging fields. Each LDL particle can load up to 100 and 400 UNITS of Gd-DO3A-diph and Gd-AAZTAC17, respectively. Their LDL adducts are taken up by human hepatoblastoma G2 (HepG2) and melanoma B16 tumor cells when added to the incubation medium. T-1 measurements of the labeled cells indicate that Gd-AAZTAC17 is significantly more efficient than Gd-DO3A-diph. Furthermore, it has been found that HepG2 hepatoma cells can internalize higher amounts of Gd-AAZTAC17 than B16 cells and the involvement of LDL receptors (LDLRs) has been demonstrated in competition assays with free LDL. Gd-AAZTAC17/LDL adduct proved to be an efficient probe in the magnetic resonance (MR) visualization of subcutaneous tumors in animal models obtained by injecting B16 melanoma cells into the right flank of mice. Finally, confocal microscopy validation of the distribution of LDL-based probes in the tumor has been obtained by doping the Gd-AAZTAC17/LDL adduct with a fluorescent phospholipid moiety.
引用
收藏
页码:1046 / 1056
页数:11
相关论文
共 50 条
  • [1] LOW-DENSITY LIPOPROTEIN RECEPTORS
    KOVANEN, PT
    CLINICS IN ENDOCRINOLOGY AND METABOLISM, 1983, 12 (01): : 243 - 255
  • [2] VERY LOW-DENSITY LIPOPROTEIN AND LOW-DENSITY LIPOPROTEIN METABOLISM - OVERVIEW
    STEINBERG, D
    JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 1979, 56 (02) : A189 - A189
  • [3] Low-density lipoprotein particles in atherosclerosis
    Qiao, Ya-Nan
    Zou, Yan-Li
    Guo, Shou-Dong
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [4] MR and fluorescent imaging of low-density lipoprotein receptors
    Li, H
    Gray, BD
    Corbin, I
    Lebherz, C
    Choi, H
    Lund-Katz, S
    Wilson, JM
    Glickson, JD
    Zhou, R
    ACADEMIC RADIOLOGY, 2004, 11 (11) : 1251 - 1259
  • [5] Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents
    Corbin, Ian R.
    Li, Hui
    Chen, Juan
    Lund-Katz, Sissel
    Zhou, Rong
    Glickson, Jerry D.
    Zheng, Gang
    NEOPLASIA, 2006, 8 (06): : 488 - 498
  • [6] Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction
    Davidson, Michael H.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (03) : S11 - S15
  • [7] LOW-DENSITY LIPOPROTEIN
    THOMPSON, GR
    ARTERIOSCLEROSIS, 1983, 3 (06): : 629 - 630
  • [8] IS HYPERTRIGLYCERIDEMIC VERY LOW-DENSITY LIPOPROTEIN A PRECURSOR OF NORMAL LOW-DENSITY LIPOPROTEIN
    OSCHRY, Y
    EISENBERG, S
    DECKELBAUM, R
    OLIVECRONA, T
    ARTERIOSCLEROSIS, 1982, 2 (05): : A442 - A442
  • [9] Evaluation of Malondialdehyde Low-Density Lipoprotein Stratified by Low-Density Lipoprotein Cholesterol
    Moriyama, Kengo
    Takahashi, Eiko
    CLINICAL LABORATORY, 2017, 63 (7-8) : 1179 - 1186
  • [10] Low-density lipoprotein and oxidised low-density lipoprotein: Their role in the development of atherosclerosis
    Hamilton, CA
    PHARMACOLOGY & THERAPEUTICS, 1997, 74 (01) : 55 - 72